Glenmark’s stunning Q1 performance: How the pharma powerhouse is dominating global markets
Glenmark Pharmaceuticals Limited (Glenmark) has announced impressive financial results for the first quarter of FY 2024-25, marked by a 6.9% increase in consolidated revenue and ... Read More
Ichnos Sciences strikes exclusive global deal with Astria Therapeutics for OX40 antibody portfolio
Ichnos Sciences, a prominent clinical-stage biotechnology firm specializing in pioneering multispecific antibodies for oncology and under the ownership of Glenmark Pharmaceuticals, has announced a momentous ... Read More